COVID-19 UPDATE: We understand those living with multiple sclerosis (MS) and their loved ones may be facing a high level of uncertainty during this serious health situation. Patient safety is Genentech’s highest priority. As a company, we are taking COVID-19 seriously and are committed to keeping the communities we serve updated with any new information we learn that could help inform health decisions related to our medicines. We believe that treatment decisions are personal and should be made between patients and their healthcare teams so please reach out to your neurologist or medical professional with questions. In addition to local Public Health guidance, or local guidance specifically issued by medical or patient associations, more information about COVID-19 can be found on the Centers for Disease Control’s (CDC) website or the World Health Organization’s website.
COVID-19, coronavirus disease 2019; ECTRIMS, European Committee for Treatment and Research in MS; IRRs, infusion-related reactions; PML, progressive multifocal leukoencephalopathy.
M-XX-00007156 (Date of preparation: October 2021)
Prescribing information
Indications vary in different countries. The local prescribing information from your country is the primary source of information on the known and potential risks associated with ocrelizumab.
Archived data reports for fatalities were last updated February 2021. Please note that there will be no further updates of these archived materials